LLY or NVO? With surging GLP-1 sales, oral obesity pills and diverging 2026 outlooks, the obesity drug race is entering a pivotal new phase.

MiniMed Group, the diabetes business of Medtronic, filed Tuesday to raise up to $784 million in an initial public offering. The Northridge, California-based firm p ...

InnovaMatrix revenue is expected to fall to approximately $20 million in 2026 from $69 million in 2025, a decline of roughly 71%, representing a headwind of approximately 2% of group revenue.

Feel tired, foggy, or irritable after eating? Learn how blood sugar spikes can happen even with a normal A1C — and what to do about them.

The scientists will develop the Human Flatus Atlas, which quantifies the dynamic range of intestinal gas production. Read ...

Tirzepatide (Zepbound, Mounjaro) is a dual-agonist GLP-1 medication. It works like a GLP-1 agonist, but also targets a ...

How often you eat can influence blood sugar stability, but the right schedule depends on your body, lifestyle, and health ...

The Danish drugmaker kicked off 2026 with its explosive obesity pill launch, but recent challenges have centered around protecting its market share.

Actxa, a Singapore-based preventive health technology company, recently announced significant enhancements to its proprietary BGEM technology, the world's first clinically backed, non-invasive, ...

Research suggests exposure to natural light may help lower blood sugar in older adults. The change isn’t huge, but it is detectable. Doctors explain the findings and stress the importance of ...

Sitting next to a window may help people with type 2 diabetes control their insulin levels, according to new research. The study, published in Cell Metabolism, found that exposure to natural light — ...

Following years in development, Finnish medtech GlucoModicum has unveiled its needle-free glucose monitoring patch, designed as a temporary reader for people with Type 2 diabetes who do not need ...